ArticleFrontiers in oncology2026
Study on the prediction of postoperative metastasis in renal cancer using perirenal fat CT radiomics combined with clinical features.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aims to develop a combined predictive model for predicting postoperative metastasis risk in renal cell carcinoma (RCC) patients based on preoperative arterial-phase Computed tomography(CT) images, integrating clinical data, perirenal fat (PRF), and tumor radiomics features. Methods: A retrospective analysis was conducted on abdominal CT images and clinical data of patients with pathologically confirmed renal cell carcinoma. Inclusion criteria included preoperative CT scanning, biopsy or surgical confirmation of RCC, and postoperative follow-up to assess metastasis status. Exclusion criteria included patients who had undergone endocrine or anti-tumor treatments. The TotalSegmentator model was used for bilateral PRF segmentation, and radiomics features were extracted. Clinical models, PRF radiomics models, and tumor radiomics models were constructed and integrated into a combined predictive model (Nomogram). The performance of the models was evaluated using receiver operating characteristic (ROC) curves and area under the ROC curve (AUC) values. Results: A total of 120 patients were included, with 36 (30%) developing postoperative metastasis. The clinical model (AUC = 0.877) identified tumor maximum diameter and neutrophil count as independent predictive factors. The PRF radiomics model (AUC = 0.841) and tumor radiomics model (AUC = 0.848) performed well. The combined model (Nomogram) achieved an AUC of 0.958, significantly outperforming the individual models. All models demonstrated good calibration, and decision curve analysis confirmed their clinical net benefit. Conclusion: The combined predictive model developed in this study, integrating preoperative clinical data, PRF, and tumor radiomics features, effectively predicts postoperative metastasis risk in RCC patients. This model provides valuable non-invasive information for preoperative metastasis risk assessment and offers reliable guidance for personalized treatment plans, highlighting the critical role of the tumor microenvironment in RCC progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.